BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Clinquest Takes Stake in Enceladus


6/26/2007 10:28:03 AM

AMSTERDAM, NETHERLANDS--(MARKET WIRE)--Jun 26, 2007 -- Enceladus Pharmaceuticals and Clinquest Group, both based in Amsterdam, the Netherlands, today announce the signing of an investment and collaboration agreement. Under the terms of the agreement, Clinquest acquires a stake in Enceladus and has led a syndicate of investors to provide additional funding. Financial details are not disclosed. Enceladus will use the new funds for the ongoing clinical development of its proprietary anti-inflammatory drug Nanocort® as a treatment for active Rheumatoid Arthritis.

"The participation of Clinquest in our activities allows us to complete the phase IIa clinical proof of concept trial with Nanocort that is currently ongoing in the Netherlands. Therefore this means a major boost to our clinical development track", said Bart Metselaar, founder and CEO of Enceladus. "Furthermore, this collaboration means that we can tap into Clinquest's vast expertise in drug development and start development of Nanocort for other indications. I am particularly pleased that, as part of the deal, Clinquest's CEO Cees Wortel will be joining the Enceladus management team as acting chief medical officer. This way, we can really benefit from his longstanding experience in clinical development."

Cees Wortel, CEO of Clinquest Group, commented on the agreement: "We strongly believe in Enceladus' technology position and the promise of Nanocort. By entering in this risk-sharing arrangement, we are able to support the further development of Nanocort and the entire liposomal development platform most efficiently. "

About Enceladus Pharmaceuticals

Enceladus Pharmaceuticals is a young drug development company originating from Utrecht University, the Netherlands. Enceladus develops Nanocort®, an innovative pharmaceutical that consists of corticosteroids (anti-inflammatory agents) packaged in specifically designed small lipid vesicles. After intravenous injection, the vesicles selectively accumulate in diseased sites in the body, where they release their anti-inflammatory content. As such, Nanocort allows for target-specific corticosteroid therapy, which is expected to result in a higher efficacy and less side effects when compared with systemic corticosteroid treatment. Potential applications of Nanocort are inflammatory disorders such as Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS) and certain types of cancer.

Nanocort is currently Enceladus' main product. The company envisions finding inventive combinations of drugs and drug carrier systems, both of which in separate form have been previously evaluated in the clinic. Using this practical approach, Enceladus can effectively design new prototype therapeutics that require relatively straightforward clinical development tracks. The company is based in Amsterdam, the Netherlands. www.enceladus.nl

About Clinquest Group

The Clinquest Group is a trusted Healthcare Product Development Organization (PDO), which offers comprehensive product development services to the bio-pharmaceutical, medical device, diagnostics and medical data industries worldwide. Clinquest provides high-level strategic consulting as well as hands-on implementation services. Clinquest is recognized as a leader in the development of new, breakthrough technologies, first-in-man clinical trials and complex clinical studies. The Clinquest Group operates through three wholly-owned subsidiaries: Clinquest Inc., Clinquest Europe and Clinquest Pharmaceutical Innovations. The company is headquartered in Amsterdam, the Netherlands, and has offices in the USA and Singapore. www.clinquest.com

Contact: Enceladus Pharmaceuticals B.V. Bart Metselaar, CEO T: +31 (0)626 946 014 E: info@enceladus.nl Kruislaan 406 1098 SM Amsterdam The Netherlands

Copyright © Hugin ASA 2007. All rights reserved.

Contact: Source: Enceladus Pharmaceuticals BV



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES